标题: wijd DuPont Reveals First Product Developed with CRISPR-Cas [打印本页] 作者: CharlesteUtete 时间: 2024-5-23 16:27 标题: wijd DuPont Reveals First Product Developed with CRISPR-Cas Mbjj Waste not want not: Conserve water, protect sources
ISLAMABAD:Catalyst Energy (Private) Limited (CEPL) h stanley cup as submitted an application to National Electric Power Regulator Authority (Nepra) for power generation licence for its 100 megawatt (MW) solar power plant. Sources told APP here that the company would set up the solar power at Quaid-e-Azam Solar Park Chishtian (Punjab) to generate 100MW electricity. Photovoltaic (PV) Cell Solar Power Plant would be used to generate electricity. The project would cost $157 million and is expected to begin commercial operation by October 2017. CEPL intends to supply power generated new balance rosa from the plant to the na adidas samba nera tional grid system.Published in The Express Tribune, February 24th, 2017.Like聽Business on Facebook, follow @TribuneBiz聽on Twitter to stay informed and join in the conversation. Amarin Corporation plc announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the new balance range of guidance provided previously.According to the com yeezy 500 pany, the MARINE trial is a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study to evaluate the efficacy and safety of 2 grams and 4 grams of AMR101 in patients with fasting triglyceride levels greater than or equal to 500 mg/dl. Patients in this trial are ch nike high dunk aracterized as having very high triglyceride levels according to the National Cholesterol Education Program Adult Treatment Panel III treatment guidelines.The primary endpoint in the MARINE trial is the percentage change in triglyceride level from baseline after 12 weeks of treatment. Consistent with the protocol for this trial, the Company expects t